RedHill Biopharma Ltd. (NASDAQ:RDHL) – FBR & Co lowered their FY2016 EPS estimates for RedHill Biopharma in a research report issued on Tuesday. FBR & Co analyst V. Bernardino now anticipates that the firm will earn ($2.30) per share for the year, down from their previous forecast of ($1.92). FBR & Co currently has a “Buy” rating on the stock. FBR & Co also issued estimates for RedHill Biopharma’s Q4 2016 earnings at ($0.65) EPS, Q1 2017 earnings at ($0.65) EPS, Q2 2017 earnings at ($0.65) EPS, Q3 2017 earnings at ($0.65) EPS, Q4 2017 earnings at $0.79 EPS and FY2017 earnings at ($1.11) EPS.

Several other brokerages have also issued reports on RDHL. Zacks Investment Research upgraded shares of RedHill Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, August 26th. HC Wainwright set a $33.00 price target on shares of RedHill Biopharma and gave the stock a “buy” rating in a research note on Friday, October 7th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.25.

Earnings History and Estimates for RedHill Biopharma (NASDAQ:RDHL)

RedHill Biopharma (NASDAQ:RDHL) opened at 11.43 on Thursday. The firm has a 50-day moving average of $12.90 and a 200-day moving average of $12.80. RedHill Biopharma has a 1-year low of $8.10 and a 1-year high of $16.54.

Hedge funds have recently added to or reduced their stakes in the stock. Bank Hapoalim BM raised its stake in RedHill Biopharma by 221.7% in the third quarter. Bank Hapoalim BM now owns 147,504 shares of the company’s stock worth $2,049,000 after buying an additional 101,654 shares in the last quarter. Van ECK Associates Corp raised its stake in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares in the last quarter. Ingalls & Snyder LLC purchased a new stake in RedHill Biopharma during the second quarter worth $451,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in RedHill Biopharma during the second quarter worth $142,000. Institutional investors and hedge funds own 15.28% of the company’s stock.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focused on the development and acquisition of late clinical-stage, orally administered drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. The Company’s products pipeline includes RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA (ABC294640), MESUPRON, RP101, RIZAPORT and RHB-101.

5 Day Chart for NASDAQ:RDHL

Receive News & Stock Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related stocks with our FREE daily email newsletter.